EXCERPT

> On Wednesday, the three-judge panel from the Patent Trial and Appeal Board (PTAB) hearing the interference case issued a judgement of no interference-in-fact, stopping UC's bid for intellectual property underpinning the most lucrative applications of genome editing.
>
> "Broad has persuaded us that the parties claim patentably distinct subject matter," the panel wrote in its decision. "[Broad's] claims, which are all limited to CRISPR/Cas9 systems in a eukaryotic environment, are not drawn to the same invention as UC's claims, which are all directed to CRISPR/Cas9 systems not restricted to any environment."

Source: https://www.genomeweb.com/gene-silencinggene-editing/broad-institute-wins-crispr-patent-interference-ip-fight-not-over